Overview
Timo Dreiseidler practices practicing medicine in Wesseling, Germany.
Mr. Dreiseidler is highly rated in 1 condition, according to our data. His clinical expertise encompasses Oral Squamous Cell Carcinoma, Oral Cancer, and Osteotomy.
He is actively involved in clinical research, co-authoring 28 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Timo Dreiseidler
Is Timo Dreiseidler a top-rated expert for Osteotomy?
MediFind is an objective health platform that identifies experts based on real-world data. Timo Dreiseidler is classified as an Advanced expert for Osteotomy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Timo Dreiseidler participate in research or clinical trials?
Yes. Timo Dreiseidler has published 28 articles and abstracts on conditions like Osteotomy. You can view a list of Timo Dreiseidler's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- OsteotomyMr. Dreiseidler isAdvanced. Learn about Osteotomy.
- Experienced
- Oral CancerMr. Dreiseidler isExperienced. Learn about Oral Cancer.
- Oral Squamous Cell CarcinomaMr. Dreiseidler isExperienced. Learn about Oral Squamous Cell Carcinoma.